Virginie Verkarre

Virginie Verkarre

Auto-generated profile, based on publicly available information

Virginie Verkarre

Hôpital Européen Georges Pompidou, AP-HP Paris centre -Université de Paris

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
GDGuillaume Davidson
Guillaume Davidson
AHAlexandra Helleux
Alexandra Helleux
YVYann VANO
Yann VANO
VLVeronique Lindner
Veronique Lindner
AFAntonin Fattori
Antonin Fattori
GMGabriel Malouf
Gabriel Malouf
Immune checkpoint inhibitors (ICI) represent the cornerstone for the treatment of patients with metastatic clear cell renal cell carcinoma (ccRCC). Despite a favorable response for a subset of patients, others experience primary progressive disease, highlighting the need to precisely understand the plasticity of cancer cells and their cross-talk with the microenvironment to better predict therapeutic response and personalize treatment. Single-cell RNA sequencing of ccRCC at different disease stages and normal adjacent tissue (NAT) from patients identified 46 cell populations, including 5 tumor subpopulations, characterized by distinct transcriptional signatures representing an epithelial-to-mesenchymal transition gradient and a novel inflamed state. Deconvolution of the tumor and microenvironment signatures in public data sets and data from the BIONIKK clinical trial (NCT02960906) revealed a strong correlation between mesenchymal-like ccRCC cells and myofibroblastic cancer-associated fibroblasts (myCAF), which are both enriched in metastases and correlate with poor patient survival. Spatial transcriptomics and multiplex immune staining uncovered the spatial proximity of mesenchymal-like ccRCC cells and myCAFs at the tumor–NAT interface. Moreover, enrichment in myCAFs was associated with primary resistance to ICI therapy in the BIONIKK clinical trial. These data highlight the epithelial–mesenchymal plasticity of ccRCC cancer cells and their relationship with myCAFs, a critical component of the microenvironment associated with poor outcome and ICI resistance. Significance: Single-cell and spatial transcriptomics reveal the proximity of mesenchymal tumor cells to myofibroblastic cancer-associated fibroblasts and their association with disease outcome and immune checkpoint inhibitor response in clear cell renal cell carcinoma.

1 March 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
AMAurélien Morini
Aurélien Morini
TDTom Drossart
Tom Drossart
MTMarc-Olivier Timsit
Marc-Olivier Timsit
MSMathilde Sibony
Mathilde Sibony
VVViorel Vasiliu
Viorel Vasiliu
VVVirginie Verkarre
Virginie Verkarre

6 September 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NBNadine Benhamouda
Nadine Benhamouda
ISIkuan Sam
Ikuan Sam
NENicolas Epaillard
Nicolas Epaillard
AGAlain Gey
Alain Gey
LPLetuan Phan
Letuan Phan
Eric TartourEric Tartour
Eric Tartour
Purpose: CD70 is a costimulatory molecule known to activate CD27-expressing T cells. CD27–CD70 interaction leads to the release of soluble CD27 (sCD27). Clear-cell renal cell carcinoma (ccRCC) expresses the highest levels of CD70 among all solid tumors; however, the clinical consequences of CD70 expression remain unclear. Experimental Design: Tumor tissue from 25 patients with ccRCC was assessed for the expression of CD27 and CD70 in situ using multiplex immunofluorescence. CD27+ T-cell phenotypes in tumors were analyzed by flow cytometry and their gene expression profile were analyzed by single-cell RNA sequencing then confirmed with public data. Baseline sCD27 was measured in 81 patients with renal cell carcinoma (RCC) treated with immunotherapy (35 for training cohort and 46 for validation cohort). Results: In the tumor microenvironment, CD27+ T cells interacted with CD70-expressing tumor cells. Compared with CD27− T cells, CD27+ T cells exhibited an apoptotic and dysfunctional signature. In patients with RCC, the intratumoral CD27–CD70 interaction was significantly correlated with the plasma sCD27 concentration. High sCD27 levels predicted poor overall survival in patients with RCC treated with anti–programmed cell death protein 1 in both the training and validation cohorts but not in patients treated with antiangiogenic therapy. Conclusions: In conclusion, we demonstrated that sCD27, a surrogate marker of T-cell dysfunction, is a predictive biomarker of resistance to immunotherapy in RCC. Given the frequent expression of CD70 and CD27 in solid tumors, our findings may be extended to other tumors.

Verified
Journal Article
Open access
PDF file
ASAudrey Simonaggio
Audrey Simonaggio
DADamien Ambrosetti
Damien Ambrosetti
VVVirginie Verkarre
Virginie Verkarre
MAMarie Auvray
Marie Auvray
Stephane OudardStephane Oudard
Stephane Oudard
YVYann VANO
Yann VANO
MiTF/TFE translocation renal cell carcinoma (tRCC) is a rare and aggressive subtype of RCC representing the most prevalent RCC in the pediatric population (up to 40%) and making up 4% of all RCCs in adults. It is characterized by translocations involving either TFE3 (TFE3-tRCC), TFEB (TFEB-tRCC) or MITF, all members of the MIT family (microphthalmia-associated transcriptional factor). TFE3-tRCC was first recognized in the World Health Organization (WHO) classification of kidney cancers in 2004. In contrast to TFEB-tRCC, TFE3-tRCC is associated with many partners that can be detected by RNA or exome sequencing. Both diagnoses of TFE3 and TFEB-tRCC are performed on morphological and immunohistochemical features, but, to date, TFE break-apart fluorescent in situ hybridization (FISH) remains the gold standard for diagnosis. The clinical behavior of tRCC is heterogeneous and more aggressive in adults. Management of metastatic tRCC is challenging, especially in the younger population, and data are scarce. Efficacy of the standard of care-targeted therapies and immune checkpoint inhibitors remains low. Recent integrative exome and RNA sequencing analyses have provided a better understanding of the biological heterogeneity, which can contribute to a better therapeutic approach. We describe the clinico-pathological entities, the response to systemic therapy and the molecular features and techniques used to diagnose tRCC.

Verified
Journal Article
Open access
PDF file
JHjinwook hwang
jinwook hwang
CDChristophe Desterke
Christophe Desterke
OFOlivier FERAUD
Olivier FERAUD
SRStephane Richard
Stephane Richard
SFSophie Ferlicot
Sophie Ferlicot
ATAli G Turhan
Ali G Turhan
Hereditary cancers with cancer-predisposing mutations represent unique models of human oncogenesis, as a driving oncogenic event is present in germline. Currently, there are no satisfactory models to study these malignancies. We report the generation of IPSC from the somatic cells of a patient with hereditary c-met-mutated papillary renal cell carcinoma (PRCC). From these cells we have generated spontaneous aggregates organizing in structures which expressed kidney markers such as PODXL and Six2. These structures expressed PRCC markers both in vitro and in vivo in NSG mice. Gene-expression profiling showed striking molecular similarities with signatures found in a large cohort of PRCC tumor samples. This analysis, applied to primary cancers with and without c-met mutation, showed overexpression of the BHLHE40 and KDM4C only in the c-met-mutated PRCC tumors, as predicted by c-met-mutated embryoid bodies transcriptome. These data therefore represent the first proof of concept of “hereditary renal cancer in a dish” model using c-met-mutated iPSC-derived embryoid bodies, opening new perspectives for discovery of novel predictive progression markers and for drug-screening for future precision-medicine strategies.

7 August 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
TDThomas Denize
Thomas Denize
PJPierre Alexandre Just
Pierre Alexandre Just
MSMathilde Sibony
Mathilde Sibony
HBHélène Blons
Hélène Blons
MTMarc Olivier Timsit
Marc Olivier Timsit
VVVirginie Verkarre
Virginie Verkarre